Skip to main content
. 2024 Feb 12;30(3):730–739. doi: 10.1038/s41591-023-02791-w

Fig. 3. Overall survival in the biomarker-marker evaluable population overall and by negative hyperselection status.

Fig. 3

a, Kaplan–Meier estimates of OS in the overall biomarker-evaluable population (all ctDNA-evaluable patients). bd Kaplan–Meier estimates of OS by negative hyperselection status in patients with left-sided primary tumors (b), patients with right-sided primary tumors (c) and the overall population (all ctDNA-evaluable patients) (d). The forest plots below the Kaplan–Meier plots in b, c and d show HR ± 95% CI. A Cox proportional hazard model without stratification factors was used to calculate HRs for group comparisons and P values for the interaction between negative hyperselection status and treatment group. Statistical tests were two-sided without adjustment for multiple comparisons.